Cell and Gene Supply Chain Services Market By Type of Service (Transportation and Logistics, Cold Chain Management, Warehousing and Distribution, Packaging and Labeling, Regulatory and Compliance Support), By End-User (Pharmaceutical and Biotechnology Companies, Research Institutions and Universities, Contract Research Organizations (CROs), Hospitals and Healthcare Providers, Cell and Gene Therapy Manufacturers), By Supply Chain Stage (Preclinical Stage, Clinical Trial Stage, Commercial Production Stage), By Mode of Transportation (Air Freight, Ground Freight, Sea Freight, Rail Freight), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Cell and Gene Supply Chain Services Market was valued at USD 1.4 billion in 2023 and will surpass USD 3.1 billion by 2030; growing at a CAGR of 12.4% during 2024 - 2030

The Cell and Gene Supply Chain Services Market is growing rapidly due to the increasing demand for cell and gene therapies, personalized medicine, and the expansion of clinical trials and manufacturing activities. These therapies are highly sensitive to temperature and handling requirements, necessitating specialized logistics solutions. The market comprises various services, including transportation and logistics, cold chain management, warehousing and distribution, packaging, and regulatory compliance, which are all crucial for maintaining the integrity and efficacy of these therapies. As the demand for gene-based treatments continues to rise, the supply chain services industry plays a pivotal role in ensuring the timely and safe delivery of life-saving therapies from production to the patient.       

Cold Chain Management Segment Is Largest Owing to Temperature Sensitivity      

Cold chain management is the largest segment within the cell and gene supply chain services market. The growth of this segment can be attributed to the temperature-sensitive nature of cell and gene therapies, which must be stored and transported at precise temperatures to maintain their efficacy. These therapies often require a controlled environment throughout the entire supply chain, from manufacturing facilities to clinical trials and eventual commercialization. The increasing number of clinical trials, particularly for gene therapies and vaccines, has accelerated the demand for advanced cold chain solutions, including refrigerated trucks, temperature-controlled containers, and cryogenic storage.  

Cold chain management encompasses the use of specialized packaging materials, real-time tracking systems, and advanced storage facilities, ensuring that the temperature requirements are met at all stages of the therapy's journey. With regulatory bodies such as the FDA and EMA imposing strict temperature and safety requirements, the demand for reliable and efficient cold chain solutions has surged. As a result, companies are investing heavily in state-of-the-art logistics infrastructure and technologies to meet the stringent demands of the market.

Pharmaceutical and Biotechnology Companies Segment Is Largest Due to Robust Demand         

Pharmaceutical and biotechnology companies represent the largest end-user segment in the cell and gene supply chain services market. These companies are leading the charge in the development and commercialization of gene therapies, which often require complex and specialized supply chain services. The rise in biotechnology innovations, along with regulatory approvals for gene therapies, has created a substantial need for temperature-sensitive logistics and compliance services. Pharmaceutical companies, in particular, are focusing on the efficient distribution of therapies to hospitals, healthcare providers, and clinical trial sites across the globe.       

Biotech companies are also increasing their research and development spending, resulting in an uptick in clinical trials for gene therapies. These trials require specialized logistics services, including cold chain management, regulatory support, and compliance monitoring to ensure the therapies remain viable throughout the trial process. Pharmaceutical and biotechnology companies are crucial to market growth, driving innovation in both the therapies they develop and the logistics solutions needed to bring these products to market.

Clinical Trial Stage Is Fastest Growing Segment Due to Increased Research and Development     

The clinical trial stage is the fastest growing segment in the cell and gene supply chain services market, driven by the increasing number of gene therapy clinical trials and research activities. As regulatory bodies approve more gene and cell therapies for clinical trials, the need for efficient and reliable supply chain solutions to support these trials becomes more pronounced. Clinical trials often involve complex logistics, including the transportation of sensitive biological materials, temperature-controlled packaging, and the monitoring of environmental conditions to maintain the integrity of the therapies being tested.    

The growth of this segment is also supported by the increasing investment in research and development from pharmaceutical companies and biotech firms, which are expanding their pipeline of cell and gene therapies. As clinical trials progress into more global markets, logistics providers are required to meet the high demands for speed, temperature sensitivity, and regulatory compliance, contributing to the growth of this segment.           

Air Freight Segment Is Largest Owing to Speed and Reliability

Air freight is the largest mode of transportation in the cell and gene supply chain services market, owing to its speed and reliability in delivering time-sensitive biological materials. Air transport ensures that therapies reach clinical trial sites or healthcare providers promptly, reducing transit times and minimizing the risk of temperature fluctuations. Gene therapies are often perishable and require swift delivery from manufacturing facilities to various locations worldwide, making air freight the preferred method of transport. 

Air freight is also crucial for transporting biologics under stringent regulatory conditions, as it is often accompanied by specialized handling procedures and temperature monitoring. The high demand for air freight in gene therapy logistics is expected to continue growing, as speed and efficiency are essential in the rapidly evolving biotech industry.      

North America Region Is Largest Due to Advanced Infrastructure and High Demand          

North America holds the largest market share in the global cell and gene supply chain services market. The region benefits from a well-established infrastructure, advanced healthcare facilities, and the presence of numerous pharmaceutical and biotechnology companies, which are major contributors to the demand for specialized supply chain services. The U.S., in particular, is a leader in the development of gene and cell therapies, with numerous companies engaged in the research, development, and commercialization of such treatments. This growth is also supported by favorable regulatory environments, such as the FDA’s approval processes for gene therapies.           

Additionally, North America’s highly developed cold chain infrastructure and advanced logistics technologies enable companies to meet the stringent requirements of temperature-sensitive therapies. As a result, North America is expected to maintain its dominance in the market for the foreseeable future, driving innovations in logistics and compliance services.

Competitive Landscape and Leading Companies

The competitive landscape of the cell and gene supply chain services market is highly fragmented, with several global players offering specialized logistics services tailored to the unique requirements of gene therapies. Leading companies include World Courier, UPS Healthcare, DHL Supply Chain, Kuehne + Nagel, and Marken, all of which provide integrated solutions for the transportation, cold chain management, packaging, and regulatory compliance of cell and gene therapies.    

These companies are focusing on expanding their cold chain capabilities, investing in innovative technologies such as real-time tracking, temperature-controlled packaging, and automated supply chain management systems. They are also forming strategic partnerships with biotechnology firms, contract research organizations (CROs), and healthcare providers to enhance service offerings and ensure the secure and efficient delivery of therapies. The market is expected to remain competitive, with companies vying for market share through technological advancements, global expansion, and improved regulatory compliance.      

Recent Developments:

• World Courier partnered with Vertex Pharmaceuticals for expanded global cell and gene therapy logistics, enhancing temperature-controlled transportation services for clinical trials.
• UPS Healthcare launched specialized cold chain solutions for biopharma, providing temperature-controlled shipping services for cell and gene therapies.
• DHL Supply Chain acquired Cold Chain Technologies to strengthen its position in the gene therapy logistics space, expanding its cold chain capabilities for the pharmaceutical and biotechnology sectors.
• Marken and BioLife Solutions collaborated to enhance storage and distribution capabilities for cell and gene therapy providers, offering comprehensive supply chain solutions.
• FedEx Express introduced Cryoport Systems for secure, temperature-sensitive gene and cell therapy transportation, ensuring compliance with regulatory standards and product safety during transit.

List of Leading Companies:

• World Courier
• UPS Healthcare
• Kuehne + Nagel
• DHL Supply Chain
• FedEx
• Ceva Logistics
• Kerry Group
• XPO Logistics
• Cold Chain Technologies
• Lineage Logistics
• Marken
• Panalpina
• Air Canada Cargo
• Biotec Services International
• BioLife Solutions

Report Scope: